Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Rapizzi

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Theranostics|August 15, 2019
Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paragangliomaBruna Calsina, Luis Jaime Castro-Vega, Rafael Torres-Pérez, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|September 1, 2024
MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paragangliomaMaría Monteagudo, Bruna Calsina, Milton E Salazar-Hidalgo, et al.
Nature Communications|February 28, 2023
Genomic and immune landscape Of metastatic pheochromocytoma and paragangliomaBruna Calsina, Elena Piñeiro-Yáñez, Ángel M Martínez-Montes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2012
MAX mutations cause hereditary and sporadic pheochromocytoma and paragangliomaNelly Burnichon, Alberto Cascón, Francesca Schiavi, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Theranostics|August 15, 2019
Integrative multi-omics analysis identifies a prognostic miRNA signature and a targetable miR-21-3p/TSC2/mTOR axis in metastatic pheochromocytoma/paragangliomaBruna Calsina, Luis Jaime Castro-Vega, Rafael Torres-Pérez, et al.
Best Practice & Research. Clinical Endocrinology & Metabolism|September 1, 2024
MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paragangliomaMaría Monteagudo, Bruna Calsina, Milton E Salazar-Hidalgo, et al.
Nature Communications|February 28, 2023
Genomic and immune landscape Of metastatic pheochromocytoma and paragangliomaBruna Calsina, Elena Piñeiro-Yáñez, Ángel M Martínez-Montes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2012
MAX mutations cause hereditary and sporadic pheochromocytoma and paragangliomaNelly Burnichon, Alberto Cascón, Francesca Schiavi, et al.
Pageof 7